Latest Advances in Lung Cancer Research

Biomarker testing decisions for lung cancer vary by type of clinician. Fewer community oncology clinicians use biomarker testing.

Liquid biopsy simpler sampling: Liquid biopsies are easier on patients, yield faster results and cost less than tissue biopsies.

Future of liquid biopsy: Analysis of tumours using biomarkers in blood is beginning to transform cancer diagnosis.

Study defines SCLC subtypes. Study provides a transformative new system to define four major groups of small-cell lung cancer.

FDA approves new liquid biopsy tests using NGS to detect tumor DNA, aiding targeted cancer therapy selection.